Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
International Journal of Clinical and Experimental Pathology|June 23, 2015
LOXL4 is downregulated in hepatocellular carcinoma with a favorable prognosisMengxin Tian, Weiren Liu, Lei Jin, et al.
American Journal of Cancer Research|October 12, 2020
High RPS3A expression correlates with low tumor immune cell infiltration and unfavorable prognosis in hepatocellular carcinoma patientsChenhao Zhou, Jialei Weng, Chunxiao Liu, et al.
Hepatology International|May 22, 2023
Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNAChenhao Zhou, Jialei Weng, Shaoqing Liu, et al.
Redox Biology|September 18, 2022
GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolismQiang Zhou, Yirui Yin, Mincheng Yu, et al.
Gastroenterology|March 2, 2023
Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular CarcinomaChenhao Zhou, Jialei Weng, Chunxiao Liu, et al.
Cancer Letters|July 12, 2025
A noninvasive and highly efficient epigenetic predictive model for efficacy of the GOLP regimen in patients with intrahepatic cholangiocarcinomaXianlong Meng, Jiacheng Lu, Xiaoyong Huang, et al.
Signal Transduction and Targeted Therapy|August 20, 2025
First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 studyGuoming Shi, Xiaoyong Huang, Liang Ma, et al.
The Lancet. Oncology|September 1, 2025
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 studyGuoming Shi, Xiaoyong Huang, Xiaowu Li, et al.
Pageof 3